[EN] SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY<br/>[FR] DERIVES D'ACIDES ARYLALCANOIQUES SUBSTITUES SERVANT D'AGONISTES DE PPAR PAN AYANT UNE FORTE ACTIVITE ANTIHYPERGLYCEMIQUE ET ANTIHYPERLIPIDEMIQUE
申请人:SHENZHEN CHIPSCREEN BIOSCIENCE
公开号:WO2004048333A1
公开(公告)日:2004-06-10
Disclosed is the preparation and pharmaceutical use of substituted arylalcanoic acid derivatives of Formula I, wherein ring A, ring B, Rl, R2, R3, R4, R5, X, Alkl, Alk2, Arl, and Ar2 are as defined in the specification. These compounds, as selective agonists activating peroxisome proliferator-activated receptors (PPAR), in particularly the RXR/PPARalpha, RXR/PPARgamma, and RXRJPPARdelta heterodimers, are useful in the treatment and/or prevention of type 2 diabetes and associated metabolic syndrome such as hypertension, obesity, insulin resistance, hyperlipidemia, hyperglycemia, hypercholesterolemia, atherosclerosis, coronary artery disease, and other cardiovascular disorders with improved side effects profile commonly associated with conventional PPARgamma agonists.
本文披露了按照公式I的替代芳基脂肪酸衍生物的制备和药用,其中环A、环B、R1、R2、R3、R4、R5、X、Alkl、Alk2、Arl和Ar2如规范中定义。这些化合物作为选择性激动剂,激活过氧化物酶体增殖物激活受体(PPAR),特别是RXR/PPARα、RXR/PPARγ和RXR/PPARδ异源二聚体,在治疗和/或预防2型糖尿病及相关代谢综合征(如高血压、肥胖、胰岛素抵抗、高脂血症、高血糖、高胆固醇血症、动脉粥样硬化、冠状动脉疾病等)方面具有用处,且常规PPARγ激动剂常见的副作用改善。